Australia's Billion Dollar Problem: Clinical Trials, The Impact on Human Life and How HealthMatch is Changing the Future of Medicine

Manuri Gunawardena was 24 and in her final years of medical school, working on a brain cancer drug trial, when she witnessed the inequities in the clinical trial industry and the impact on human life. One patient in the trial was able to navigate the complex system and access a clinical trial and drug that was successful in curing their disease, another was not and sadly passed away.
Manuri made her own life-changing decision and, instead of becoming a clinician, founded HealthMatch. HealthMatch is a platform that empowers patients to identify and access clinical trials, changing the lives of people who need to access clinical trials and the future of medicine in Australia and across the world.
Clinical trials are worth $1 billion to Australia’s economy, yet 80% of trials are delayed or abandoned, impacting on the lives of the tens of thousands of people who need access to these often life-saving drugs. Why? 
There are fundamental issues with the clinical trial model. It’s inefficient and inequitable, archaic and broken, the very opposite of customer-centric. We see data and technology used to drive innovation and create personalised experiences in almost every other industry, so why not this one? Why has the clinical trial industry fallen so far behind?

Manuri Gunawardena was 24 and in her final years of medical school, working on a brain cancer drug trial, when she witnessed the inequities in the clinical trial industry and the impact on human life. One patient in the trial was able to navigate the complex system and access a clinical trial and drug that was successful in curing their disease, another was not and sadly passed away.

Manuri made her own life-changing decision and, instead of becoming a clinician, founded HealthMatch. HealthMatch is a platform that empowers patients to identify and access clinical trials, changing the lives of people who need to access clinical trials and the future of medicine in Australia and across the world.

Clinical trials are worth $1 billion to Australia’s economy, yet 80% of trials are delayed or abandoned, impacting on the lives of the tens of thousands of people who need access to these often life-saving drugs. Why? 

There are fundamental issues with the clinical trial model. It’s inefficient and inequitable, archaic and broken, the very opposite of customer-centric. We see data and technology used to drive innovation and create personalised experiences in almost every other industry, so why not this one? Why has the clinical trial industry fallen so far behind?